Studies have found that statins may not help reduce the mortality or severity of COVID-19

However, a recent study led by the Johns Hopkins School of Medicine conducted a 4-month study of nearly 4,500 COVID-19 hospitalized patients and provided stronger evidence for a very different conclusion: statins May not have any positive or negative impact on COVID-19-related mortality, and may be related to a significant increase in the risk of serious diseases (nearly one-fifth)

This research will be published in the journal "Public Science Library General" on September 10, 2021

"Although statins have obvious beneficial effects on the prognosis of various infectious diseases, our research shows that it may not be worthwhile to specifically treat COVID-19," the senior author of the study, Johns Hopkins Said Petros Karakousis, MD, professor of medicine at the University School of Medicine

In this study, Karakusis and colleagues reviewed the records of 4447 patients who were diagnosed with SARS-CoV-2 infection between March 1 and June 30, 2020.

To be included in the death rate associated with covid -19, one must die of illness during hospitalization

After considering other known factors that may distort the data, the researchers found that the use of statins had no significant impact on the mortality rate of COVID-19

Karakousis said: “A reasonable explanation for this discovery is that statins increase the cell production of angiotensin-converting enzyme 2 (commonly called ACE2), which is a receptor on the cell surface through which SARS-CoV-2 Enter the cell

Karakousis said that future research should try to better define the relationship between statin use and COVID-19

Karakousis said: “All the studies published so far, including ours, are retrospective, which means that no matter how hard people try to eliminate factors related to the adverse COVID-19 outcome in addition to statin use, some factors may still remain At work

Karakousis said that the only way to determine whether statins have any benefit for COVID-19 patients is to conduct clinical trials where randomized patients receive statins or placebos in addition to standard treatment

Journal Reference :

1. Samuel K.